A Role for P-Glycoprotein in Regulating Cell Death

References

• Ueda K, Cardarelli C, Gottesman M M, Pastan I. Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblast-ine. Proc. Natl. Acad. Sci. USA 1987; 84: 3004–3008
   PubMed Web of Science ®Google Scholar
• Gottesman M M, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 1993; 62: 385427
   Web of Science ®Google Scholar
• Higgins C F, Gottesman M M. Is the multidrug transporter a flippase?. Trends Biochem. Sci. 1997; 17: 18–21, 1997
   Web of Science ®Google Scholar
• Cordon-Cardo C, O'Brien J P, Boccia J, Casals D, Bertino J R, Melamed M R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 1990; 38: 12777–1287
   Google Scholar
• Klimecki W T, Futscher B W, Grogan T M, Dalton W S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451–2458
   PubMed Web of Science ®Google Scholar
• Randolph G J, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman R M, Muller W A. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl. Acad. Sci. USA. 1998; 95: 6924–6929
   PubMed Web of Science ®Google Scholar
• Schinkel A H, Smit J J, van Tellingen O, Beijnen J H, Wagenaar E, van Deemter L, Mol C A, van der Valk M A, Robanus-Maandag E C, te Riele H P, Borst P. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491–502
   PubMed Web of Science ®Google Scholar
• Schinkel A H, Mayer U, Wagenaar E, Mol C A, van Deemter L, Smit J J, van der Valk M A, Voordouw A C, Spits H, van Tellingen O, Zijlmans J M, Fibbe W E, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA. 1997; 94: 4028–4033
   PubMed Web of Science ®Google Scholar
• Panwala C M, Jones J C, Viney J L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdrla, spontaneously develop colitis. J. Immunol. 1998; 161: 5733–5744
   PubMed Web of Science ®Google Scholar
• Valverde M A, Diaz M, Sepulveda F V, Gill D R, Hyde S C, Higgins C F. Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 1992; 355: 830–833
   PubMed Web of Science ®Google Scholar
• Gill D R, Hyde S C, Higgins C F, Valverde M A, Mintenig G M, Sepulveda F V. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 1992; 71: 23–32
   PubMed Web of Science ®Google Scholar
• Hardy S P, Goodfellow H R, Valverde M A, Gill D R, Sepulveda V, Higgins C F. Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBOJ. 1995; 14: 68–75
   PubMed Web of Science ®Google Scholar
• Bwd T D, Valverde M A, Higgins C F. Protein kinase C phosphorylation disengages human and mouse-la P-glycoproteins from influencing the rate of activation of swelling-activated chloride currents. J. Physiol. 1998; 508: 333–340
   PubMed Web of Science ®Google Scholar
• van Helvoort A, Smith A J, Sprong H, Fritzsche I, Schinkel A H, Borst P, van Meer G. MDRl P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996; 87: 507–517
   PubMed Web of Science ®Google Scholar
• Bosch I, Dunussi-Joannopoulos K, Wu R L, Furlong S T, Croop J. Phosphatidylcholine and phosphatidyleth-anolamine behave as substrates of the human MDRl P-glycoprotein. Biochemistry 1997; 36: 5685–5694
   PubMed Web of Science ®Google Scholar
• Debry P, Nash E A, Neklason D W, Metherall J E. Role of Multidrug Resistance P-glycoproteins in Cholesterol Esterification. J. Biol. Chem. 1997; 272: 1026–1031
   PubMed Web of Science ®Google Scholar
• Luker G D, Nilsson K R, Covey D F, Piwnica-Worms D. Multidrug resistance (MDRI) P-glycoprotein enhances esterification of plasma membrane cholesterol. J. Biol. Chem. 1999; 274: 6979–6991
   PubMed Web of Science ®Google Scholar
• Raghu G, Park S W, Roninson I B, Mechetner E B. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-acti-vated lymphocytes. Exp. Hematol. 1996; 24: 1258–1264
   PubMed Web of Science ®Google Scholar
• Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreef M, Huber H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human Tlymphocytes. Blood 1996; 88: 1747–1754
   PubMed Web of Science ®Google Scholar
• Weisburg J H, Curcio M, Caron P C, Raghu G, Mechetner E B, Roepe P D, Scheinberg D A. The multidrug resistance phenotype confers immunological resistance. J. Exp. Med. 1996; 183: 2699–2704
   PubMed Web of Science ®Google Scholar
• Robinson U, Roberts W K, Ling T T, Lamming D, Sternberg S S, Roepe P D. Human MDRl protein overexpres-sion delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997; 36: 11169–11178
   PubMed Web of Science ®Google Scholar
• Smyth M J, Krasovskis E, Sutton V R, Johnstone R W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA 1998; 95: 7024–7029
   PubMed Web of Science ®Google Scholar
• Johnstone R W, Cretney E, Smyth M J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-indepependent cell death. Blood 1999; 93: 1075–1085
   PubMed Web of Science ®Google Scholar
• Geyp M, Ireland C M, Pittman S M. Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line. Leukemia 1996; 10: 447455
   Google Scholar
• Malorni W, Rainaldi G, Tritarelli E, Rivabene R, Cianfriglia M, Lehnert M, Donelli G, Peschele C, Testa U. Tumor necrosis factor alpha is a powerful apoptotic inducer in lymphoid leukemic cells expressing the P-170 glycoprotein. Int J Cancer 1996; 67: 238–247
   PubMed Web of Science ®Google Scholar
• Robinson L J, Roepe P D. Effects of membrane potential versus pHi on the cellular retention of doxorubicin analyzed via a comparison between cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance (MDR) transfectants. Biochem. Pharmacol. 1996; 52: 1081–1095
   PubMed Web of Science ®Google Scholar
• Roepe P D. The role of the MDR protein in altered drug translocation across tumor cell membranes. Biochim. Biophys. Acta. 1995; 1241: 385405
   Google Scholar
• Roepe P D, Wei L Y, Cruz J, Carlson D. Lower electrical membrane potential and altered pHi homeostasis in multi-drug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 1993; 32: 11042–11056
   PubMed Web of Science ®Google Scholar
• Hoffman M M, Wei L Y, Roepe P D. Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance?. J. Gen. Physiol. 1996; 108: 295–313
   PubMed Web of Science ®Google Scholar
• Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou J P. Restoration of TNF-alpha-induced cera-mide generation and apoptosis in resistant human leukemia KGla cells by the P-glycoprotein blocker PSC833. FASEB J. 1998; 12: 101–109
   PubMed Web of Science ®Google Scholar
• Hoffman M M, Roepe P D. Analysis of ion transport perturbations caused by hu MDR 1 protein overexpression. Biochemistry 1997; 36: 11153–68
   PubMed Web of Science ®Google Scholar
• Hunnun Y A. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845–1853
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365
   PubMed Web of Science ®Google Scholar
• Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K M. Cross-resistance of CD95– and drug-induced apoptosis as a consequence of deficient activation of caspases (ICWCed-3 proteases). Blood 1997; 90: 3118–3129
   PubMed Web of Science ®Google Scholar
• Friesen C, Herr I, Krammer P H, Debatin K -M. Involvement of the CD95 (ApoVFas) receptor/ligand system in drug-induced apoptosis in leukemia ells. Nat. Med. 1996; 2: 574–577
   PubMed Web of Science ®Google Scholar
• Fulda S, Los M, Friesen C, Debatin K M. Chemosen-sitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer 1997; 76: 05–114
   Google Scholar
• Eischen C M, Kottke T J, Martins L M, Basi G S, Tung J S, Earnshaw W C, Leibson P J, Kaufmann S C. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 1997; 90: 935–943
   PubMed Web of Science ®Google Scholar
• Villunger A, Egle A, Kos M, Hartmann B L, Geley S, Kofler R, Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 1997; 57: 3331–3334
   PubMed Web of Science ®Google Scholar
• Walsh C M, Wen B G, Chinnaiyan A M, O'Rourke K, Dixit V M, Hedrick S M. A role for FADD in T cell activation and development. Immunity 1998; 8: 439–449
   PubMed Web of Science ®Google Scholar
• Newton K, Harris A W, Bath M L, Smith K GC, Strasser A. A dominant interfering mutant of FADD/MORTI enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 1998; 17: 706–718
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed J C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar
• Schmitt E, Cimoli G, Steyaert A, Bertrand R. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities. Exp. Cell. Res. 1998; 240: 107–21
   PubMed Web of Science ®Google Scholar
• Ruefli A A, Smyth M J, Johnstone R W. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein mediated multidrug resistance. Blood 1999, In press
   Google Scholar
• Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375: 78–81
   PubMed Web of Science ®Google Scholar
• Van de Los M, Craen M, Penning L C, Schenk H, Westendorp M, Baeuerle P A, Droge W, Krammer P H, Fiers W, Schulze-Osthoff K. Requirement of an ICE/CED-3 protease for Fas/APO-I-mediated apoptosis. Nature 1995; 375: 81–83
   PubMed Web of Science ®Google Scholar
• Longthorne V L, Williams G T. Caspase activity is required for commitment to Fas-mediated apoptosis. EMBOJ. 1997; 16: 3805–3812
   PubMed Web of Science ®Google Scholar
• Katsikis P D, Garcia-Ojeda M E, Torres-Roca J F, Tijoe I M, Smith C A, Herzenberg L A, Herzenberg L A. Inter-leukin-I beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apopto-sis-inducing ligand can mediate activation-induced T cell death in HIV infection. J. Exp. Med. 1997; 186: 1365–1372
   PubMed Web of Science ®Google Scholar
• Vanags D M, Porn-Ares M I, Coppola S, Burgess D H, Orren-ius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J. Biol. Chem. 1997; 271: 31075–31085
   Web of Science ®Google Scholar
• Tewari M, Dixit V M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 1995; 270: 3255–3260
   PubMed Web of Science ®Google Scholar
• Beidler D R, Tewari M, Friesen P D, Poirier G, Dixit V M. The baculovirus p35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis. J. Biol. Chem. 1995; 270: 16526–16538
   PubMed Web of Science ®Google Scholar
• Rehemtulla A, Hamilton C A, Chinnaiyan A R, Dixit V M. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-I). J. Biol. Chem. 1997; 272: 25783–25786
   PubMed Web of Science ®Google Scholar
• Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and adaptor signal trans-duction: lessons from knockout mice. Immunity 1999; 10: 629–639
   PubMed Web of Science ®Google Scholar
• Ruefli A A, Tainton K M, Smyth M J, Johnstone R W. 1999, Unpublished observations
   Google Scholar
• Dong Z, Saikumar P, Weinberg J M, Venkatachalam M A. Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of senne but not cysteine proteases. Am. J. Pathol. 1997; 151: 1205–1213
   PubMed Web of Science ®Google Scholar
• Trapani J A, Jans D A, Jans P J, Smyth M J, Browne K A, Sut-ton V R. Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent. J. Biol. Chem. 1998; 273: 27934–27938
   PubMed Web of Science ®Google Scholar
• Browne K A, Blink E, Sutton V R, Froelich C J, Jans D A, Trapani J A. Bacterial toxins can replace perforin to facilitate cytosolic delivery of granzyme B: evidence that endosomal disruption is an important function of perforin, in addition to transmembrane pore-formation. Mol. Cell. Biol. 1999, In press
   PubMed Web of Science ®Google Scholar
• Shinkai Y, Takio K, Okumura K. Homology of perforin to the ninth component of complement (C9). Nature 1988; 334: 525–527
   PubMed Web of Science ®Google Scholar
• Andreeff M, Stone R, Michaeli J, Young C W, Tong W P, Sogolof H, Ervin T, Kufe D, Rifkind R A, Marks P A. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemic: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80: 2604–2609
   PubMed Web of Science ®Google Scholar
• Marks P A, Richon V M, Rifkind R A. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. Int. J. Hematol. 1996; 63: 1–17
   PubMed Web of Science ®Google Scholar
• Siegel D S, Zhang X, Feinman R, Teitz T, Zelenetz A, Richon V M, Rifkind R A, Marks P A, Michaeli J. Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proc Natl Acad Sci USA 1998; 95: 162
   PubMed Web of Science ®Google Scholar
• Trapani J A, Sutton V R, Smyth M J. CTL granules: evolution of vesicles essential for combating virus infections. Immunol. Today 1999; 20: 351–356
   PubMedGoogle Scholar
• Lavoie J N, Nguyen M, Marcellus R C, Branton P E, Shore G C. E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J. Cell. Biol. 1998; 140: 637–644
   PubMed Web of Science ®Google Scholar
• Deas O, Durnont C, MacFarlane M, Rouleau M, Hebib C, Harper F, Hirsch F, Charpentier B, Cohen G M, Senik A. Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes. J Immunol. J Immunology 1997; 161: 3375–3380
   Google Scholar
• De Maria R, Lenti L, Malisan F, d'Agostin F, Tomassini B, Zeuner A, Rippo M R, Testi R. Requirement for the GD3 ganglioside in CD95– and ceramide-induced apoptosis. Science 1997; 277: 1652–1655
   PubMed Web of Science ®Google Scholar
• Bossy-Wetzel E, Newmeyer D D, Green D R. Mito-chondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 1998; 17: 37–43
   PubMed Web of Science ®Google Scholar
• Miller T M, Moulder K L, Knudson C M, Creedon D J, Desh-mukh M, Korsmeyer S J, Johnson E M, Jr. Bax deletion further orders the cell death pathway in cerebellar granule cells and suggests a caspase-independent pathway to cell death. J. Cell. Biol. 1997; 139: 205–210
   PubMed Web of Science ®Google Scholar
• Muzio M, Chinnaiyan A M, Kischkel F C, Orourke K, Shevchenko A, Ni J, Scaffidi C, Bretz J D, Zhang M, Gentz R, Mann M, Krammer P H, Peter M E, Dixit V M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-I) death-inducing signaling complex. Cell 1996; 85: 817–827
   PubMed Web of Science ®Google Scholar
• Gottlieb R A, Giesing H A, Zhu J Y, Engler R L, Babior B M. Cell acidification in apoptosis: granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H+-ATPase. Proc. Natl. Acad. Sci. USA 1995; 92: 5965–5968
   PubMed Web of Science ®Google Scholar
• Furlong I J, Ascaso R, Rivas A L, Collins M U. Intra-cellular acidification induces apoptosis by stimulating ICE-like protease activity. J. Cell. Sci. 1997; 110: 653–661
   PubMed Web of Science ®Google Scholar
• Stennicke H R, Salvesen G S. Biochemical charactcristics of caspases-3, -6, -7, and -8. J. Biol. Chem. 1997; 272: 25719–25723
   PubMed Web of Science ®Google Scholar
• Garcia-Calvo M, Peterson E P, Rasper D M, Vaillancourt J P, Zamboni R, Nicholson D W, Thombeny N A. Purification and catalytic properties of human caspase family members. Cell. Death. Differ. 1999; 6: 362–369
   PubMed Web of Science ®Google Scholar
• Gottlieb R A, Nordberg J, Skowronski E, Babior B M. Apoptosis induced in Jurkat cells by several agents is preceded by intraceliular acidification. Proc. Natl. Acad. Sci. USA 1996; 93: 654–658
   PubMed Web of Science ®Google Scholar
• Weisburg J H, Roepe P D, Dzekunov S, Scheinberg D A. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J. Biol. Chem. 1999; 274: 10877–10888
   PubMed Web of Science ®Google Scholar
• Dalmasso A P, Lelchuk R, Giavedoni E B, De Isola E D. The modifications of the final stages of the complement reaction by alkali metal cations. J. Immunol. 1975; 115: 63–68
   PubMed Web of Science ®Google Scholar
• Alouf J E, Geoffroy C, Pattus F, Verger R. Surface properties of bacterial sulfhydryl-activated cytolytic toxins. Interaction with monomolecular films of phosphatidylcho-line and various sterols. Eur. J. Biochem. 1984; 141: 205–210
   PubMedGoogle Scholar
• Young J D, Damiano A, DiNome M A, Leong L G, Cohn Z A. Dissociation of membrane binding and lytic activites of the lymphocyte pore-forming protein (perforin). J. Exp. Med. 1987; 165: 1371–1382
   PubMed Web of Science ®Google Scholar
• Esser A F, Kolb W P, Podack E R, Muller-Eberhard H J. Molecular reorganization of lipid bilayers by complement: a possible mechanism for membranolysis. Proc. Natl. Acad. Sci. USA 1979; 76: 1410–1414
   PubMed Web of Science ®Google Scholar
• Anita R, Schlegal R A, Williamson P. Binding of perforin to membranes is sensitive to lipid spacing but not head-groups. Immunol. Letts. 1992; 32: 153–158
   PubMed Web of Science ®Google Scholar
• Uellner R, Zveiebil M J, Hopkins J, Jones J, MacDougall L K, Morgan B P, Podack E, Waterfield M D, Griffiths G M. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBOJ. 1997; 16: 7287–7296
   PubMed Web of Science ®Google Scholar
• Bunting K D, Galipeau J, Topham D, Benaim E, Sorrentino B P. Transduction of bone marrow cells with an MDRl vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 1998; 92: 2269–2279
   PubMed Web of Science ®Google Scholar
• Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 1994; 77: 1071–81
   PubMed Web of Science ®Google Scholar